Lonza and Touchlight collaborate on end-to-end mRNA offering
Touchlight awarded ILAP for therapeutic DNA vaccine
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Touchlight and Versameb announce GMP manufacturing supply agreement
AskBio and Touchlight Restructure Joint Venture
Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50
Touchlight to break ground on world’s highest-capacity DNA manufacturing facility
Touchlight expands commercial team amid rapid company growth
Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand
Touchlight appoints Satish Muchakayala as Director of Regulatory Affairs
mRNA-based therapeutics summit
Join us at the mRNA-based therapeutics summit in Boston, US (July 26-28, 2023).
Our team will be available to discuss your advanced therapy manufacturing. Learn how our enzymatically produced DNA vector called doggybone DNA (dbDNA) can significantly improve speed to manufacture, safety and scalability in comparison to plasmid DNA, for vaccine development.